Explore

Trendline Trendline
AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum

AN2 Therapeutics to Engage in 2026 Stifel Virtual Targeted Oncology Forum
Trendline Trendline
Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline

Zai Lab Reports Q1 2026 Financial Results and Advances Oncology Pipeline
Trendline Trendline
Gilead Cuts 87% of Arcellx Workforce Following Acquisition

Gilead Cuts 87% of Arcellx Workforce Following Acquisition

Gilead Cuts 87% of Arcellx Workforce Following Acquisition
Trendline Trendline
TORL BioTherapeutics Appoints Aran Maree as CEO to Lead Next Growth Phase

TORL BioTherapeutics Appoints Aran Maree as CEO to Lead Next Growth Phase

TORL BioTherapeutics Appoints Aran Maree as CEO to Lead Next Growth Phase
Trendline Trendline
Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs

Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs

Vir Biotechnology Reports Strong Financial Position and Advances in Cancer and Hepatitis Delta Programs
Trendline Trendline
Generate Biomedicines Reports Q1 2026 Financial Results Amid Clinical Advancements

Generate Biomedicines Reports Q1 2026 Financial Results Amid Clinical Advancements

Generate Biomedicines Reports Q1 2026 Financial Results Amid Clinical Advancements
Trendline Trendline
Vir Biotechnology to Present at Bank of America Healthcare Conference

Vir Biotechnology to Present at Bank of America Healthcare Conference

Vir Biotechnology to Present at Bank of America Healthcare Conference
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion

Nuvectis Pharma Reports Increased Net Loss in Q1 2026 Amid Clinical Expansion
Trendline Trendline
Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead
Trendline Trendline
Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026
Trendline Trendline
Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones

Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones

Contineum Therapeutics Reports Q1 2026 Financial Results and Clinical Milestones
Trendline Trendline
Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer